Biorelate Secures £6.5 Million for Biotech Expansion
Biorelate, a pioneering biotech company based in Manchester, UK, has successfully raised £6.5 million in a Series A funding round. This significant financial injection was led by Maven Capital Partners and YFM Equity Partners, two prominent investors in the biotech landscape. The funding was procured through VCTs that YFM operates, alongside the Maven VCTs and Triple Point Ventures. Additionally, the Northern Powerhouse Investment Fund, managed by Maven and involving contributions from a range of angel investors associated with the Manchester Tech Trust, played a crucial role in supporting this funding initiative. With this capital boost, Biorelate is poised to advance its strategic plans aimed at expanding operations and scaling its innovative projects.
Founded in 2014 and under the leadership of CEO Daniel Jamieson, Biorelate has carved out a niche in the biotech industry by curating dark biomedical knowledge through its advanced AI platform, Galactic AI.
This cutting-edge technology leverages natural language processing (NLP) and machine learning (ML) to sift through vast amounts of biomedical data, capturing essential insights that can help pharmaceutical and life sciences organizations refine their decision-making processes in drug discovery. The innovative approach exemplified by Biorelate’s Galactic AI is not merely a technical feat but a transformational tool that holds the potential to reshape the dynamics of drug discovery and development.
Since the launch of Galactic AI™ in 2020, Biorelate has witnessed remarkable growth, securing partnerships with some of the most influential global companies in the industry, including AstraZeneca and Idorsia. These collaborations, alongside various other undisclosed clients, underscore the platform's effectiveness and relevance in a sector that demands speed and accuracy. As Biorelate plans to utilize its newly acquired funding to enhance its product offerings, expand its sales and marketing capabilities, and ultimately establish a foothold in the US market, the company stands at the forefront of innovation in drug discovery, paving the way for future advancements in biomedical research.
They've invested in Biorelate
Get to know these Healthtech investors
| # | Investor | Sector | Stage | Activity | Team | Connect |
|---|---|---|---|---|---|---|
1 |  Maven Capital Partners | 11 investment(s) investment(s) | more info | |||
2 |  YFM Equity Partners | 9 investment(s) investment(s) | 10 contacts contacts | |||
3 |  Northern Powerhouse Investment Fund | 1 investment(s) investment(s) | more info | |||
4 |  Triple Point Ventures | 7 investment(s) investment(s) | more info |
Click here for a full list of 6,528+ startup investors in the UK